Arterial Thromboembolism Incidence in Japanese Patients With Lung Cancer
Cancer Medicine · 2025
DOI: 10.1002/cam4.71356 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Kazuki Fukuzawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Data Science, Medical Division, Osaka, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Thromboembolism. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Background
Patients with lung cancer tend to have a high incidence of arterial thromboembolism (ATE). However, although ATE is a life‐threatening disease, there are insufficient studies evaluating patient characteristics associated with a high risk of ATE in patients with lung cancer. This study aimed to examine the incidence of ATE in Japanese patients with lung cancer and evaluate the incidence of ATE by histological types and treatment patterns to identify high‐risk groups.
Methods
We conducted a retrospective cohort study using the National Health Insurance (NHI), Employees' Health Insurance (EHI), and Later‐Stage Elderly Healthcare System (LSEHS) claims databases from April 1, 2014, to March 31, 2022. The patients were followed up for up to 5 years after lung cancer diagnosis. The cumulative incidence rates of ATE were calculated, and the histological subtype and treatment pattern were analyzed using the Cox proportional hazards model.
Results
Among 6340 patients in EHI, 10,857 patients in NHI, and 13,039 patients in LSEHS, patient characteristics such as the median age and the prevalence of comorbidities were different among the three databases. The cumulative incidence rates at 1 year were 1.7%, 4.5%, and 7.2%, and those at 5 years were 3.5%, 8.0%, and 15.9%. The adjusted hazard ratio for small cell lung cancer compared to non‐small cell lung cancer was 2.84 (95% confidence interval (CI): 1.46–5.54) in EHI, 0.93 (95% CI: 0.65–1.32) in NHI, and 1.11 (95% CI: 0.85–1.46) in LSEHS. The risk of ATE of RT + systemic therapy and systemic therapy only was higher than surgery only, with a statistically significant difference in the three databases.
Conclusion
In any database, the cumulative incidence of ATE increased over the 5 year observation period. Patients who received RT + systemic therapy and those who received systemic therapy only had a higher risk of ATE than those who underwent surgery only.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Data Science, Medical Division, Osaka, Japan.
- Department of Environmental Medicine and Population Science, Graduate School of Medicine, Osaka University, Osaka, Japan.
- Medical Science Department, Late Development Oncology TA Division, Research & Development, Tokyo, Japan.
ORCID-Profile: Kazuki Fukuzawa, Yoshimitsu Shimomura, Ling Zha
Förderung
- AstraZeneca
Zitieren
APA
Fukuzawa, K., Shimomura, Y., Zha, L., Shida, H., Hayama, M., Kitamura, T., & Horie, Y. (2025). Arterial Thromboembolism Incidence in Japanese Patients With Lung Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71356
Vancouver
Fukuzawa K, Shimomura Y, Zha L, Shida H, Hayama M, Kitamura T, et al. Arterial Thromboembolism Incidence in Japanese Patients With Lung Cancer. Cancer Medicine. 2025. doi:10.1002/cam4.71356
BibTeX
@article{Fukuzawa2025,
author = {Fukuzawa, Kazuki and Shimomura, Yoshimitsu and Zha, Ling and Shida, Haruka and Hayama, Manabu and Kitamura, Tetsuhisa and Horie, Yoshiharu},
title = {Arterial Thromboembolism Incidence in Japanese Patients With Lung Cancer},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71356}
}
EUVIMED